GeoVax Labs (GOVX)
(Delayed Data from NSDQ)
$2.01 USD
-0.02 (-0.99%)
Updated Oct 14, 2024 04:00 PM ET
After-Market: $2.00 -0.01 (-0.50%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Brokerage Reports
0 items in cart
GeoVax Labs Inc. [GOVX]
Reports for Purchase
Showing records 1 - 20 ( 73 total )
Company: GeoVax Labs Inc.
Industry: Medical - Biomedical and Genetics
GEO-CM04S1 Garnered Significant Funding in 2Q24; Reiterate Buy and $8 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: GeoVax Labs Inc.
Industry: Medical - Biomedical and Genetics
2Q24: All Clinical Programs On Track, More GEO-CM04S1 Data Coming Over 2H24
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: GeoVax Labs Inc.
Industry: Medical - Biomedical and Genetics
Company: GeoVax Labs Inc.
Industry: Medical - Biomedical and Genetics
Aiming To Address The Underserved At An Expedited Pace - Initiate At Buy
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: GeoVax Labs Inc.
Industry: Medical - Biomedical and Genetics
Allucent Signed to Advance COVID-19 Vaccine Into Phase 2b; Reiterate Buy and $8 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: GeoVax Labs Inc.
Industry: Medical - Biomedical and Genetics
BARDA Award to Advance GEO-CM04S1; Reiterate Buy and Adjust PT to $8 Post Reverse Split
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: GeoVax Labs Inc.
Industry: Medical - Biomedical and Genetics
Company: GeoVax Labs Inc.
Industry: Medical - Biomedical and Genetics
Reports Full Year 2023 - $6.5M in Cash, Expect a Raise, The Project NextGen (Covid) Award from BARDA Could be a Key Catalyst
Provider: Dawson James Securities, Inc.
Analyst: KOLBERT J
Company: GeoVax Labs Inc.
Industry: Medical - Biomedical and Genetics
Model Revised Introducing a $5.0 Price Target
Provider: Dawson James Securities, Inc.
Analyst: KOLBERT J
Company: GeoVax Labs Inc.
Industry: Medical - Biomedical and Genetics
1 for 15 Reverse Split Effected, Model Under Review
Provider: Dawson James Securities, Inc.
Analyst: KOLBERT J
Company: GeoVax Labs Inc.
Industry: Medical - Biomedical and Genetics
Enters a Common Stock Warrant Exercise - $4.4M Expected
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: GeoVax Labs Inc.
Industry: Medical - Biomedical and Genetics
Company: GeoVax Labs Inc.
Industry: Medical - Biomedical and Genetics
3Q23 Results: Recent Milestones Position Clinical Programs for Important Near-Term Data Readouts; Reit. Buy and $8 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: GeoVax Labs Inc.
Industry: Medical - Biomedical and Genetics
GeoVax Labs: Reported the Quarter - Data Ahead
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: GeoVax Labs Inc.
Industry: Medical - Biomedical and Genetics
GeoVax Labs: Expands Clinical Sites for P2 COVID Vaccine
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: GeoVax Labs Inc.
Industry: Medical - Biomedical and Genetics
Company: GeoVax Labs Inc.
Industry: Medical - Biomedical and Genetics
Company: GeoVax Labs Inc.
Industry: Medical - Biomedical and Genetics
Notice of Patent Allowance For Marburg Further Expands Freedom to Operate; Reiterate Buy Rating and $8 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: GeoVax Labs Inc.
Industry: Medical - Biomedical and Genetics
GeoVax Labs Secures License for ProBioGen''s Manufacturing
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: GeoVax Labs Inc.
Industry: Medical - Biomedical and Genetics
GeoVax Labs Announces Publication of GEO-CM04S1 Data
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J